| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/13/2005 | EP1522591A2 Transgenically produced non-secreted proteins |
| 04/13/2005 | EP1522310A1 Therapeutic uses of dunaliella powder |
| 04/13/2005 | EP1521839A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521822A2 Protein modification and maintenance molecules |
| 04/13/2005 | EP1521773A1 Phosphoinositolglycan (pig)-binding protein from adipocytes |
| 04/13/2005 | EP1521744A1 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists |
| 04/13/2005 | EP1521743A1 Hmg-coa reductase inhibitors |
| 04/13/2005 | EP1521742A1 Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
| 04/13/2005 | EP1521740A2 Probucol derivatives |
| 04/13/2005 | EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 04/13/2005 | EP1521594A2 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 04/13/2005 | EP1521584A1 Purine derivatives as liver x receptor agonists |
| 04/13/2005 | EP1521583A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives |
| 04/13/2005 | EP1521574A1 Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof |
| 04/13/2005 | EP1307185B1 Use of carboanhydrase inhibitors for the prevention of diabetic retinopathy in diabetics |
| 04/13/2005 | EP1303296B1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/13/2005 | EP1289955B1 Piperidines for use as orexin receptor antagonists |
| 04/13/2005 | EP1268498B1 Cardioprotective phosphonates |
| 04/13/2005 | EP1257270B1 A method for synthesizing leflunomide |
| 04/13/2005 | EP1196136B1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/13/2005 | EP1115409A4 Composition for extending post meal satiety |
| 04/13/2005 | EP1017408B1 Use of tethrahydrolipstatin in the treatment of diabetes type ii |
| 04/13/2005 | CN1606563A Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 04/13/2005 | CN1606555A Imidazoquinoline derivatives |
| 04/13/2005 | CN1606554A Beta-lactamyl vasopressin v1aantagonists |
| 04/13/2005 | CN1606549A Thiazolidine derivative and medicinal use thereof |
| 04/13/2005 | CN1606545A Pyrrolidine and piperidine derivates as nk1 antagonists |
| 04/13/2005 | CN1606544A Bicyclic compound |
| 04/13/2005 | CN1606472A Adsorbent for phosphoric acid |
| 04/13/2005 | CN1606444A Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/13/2005 | CN1606440A Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them |
| 04/13/2005 | CN1606436A Compounds and methods of treating transplant rejection |
| 04/13/2005 | CN1606427A Stable surfactant compositions for suspending components |
| 04/13/2005 | CN1605592A Protease resistant mutein of human ciliary neurotrophic factor and its preparation and use |
| 04/13/2005 | CN1605357A Fenugreek seed extract and its preparing process and application |
| 04/13/2005 | CN1605347A Preparation and application of red rice dispersible tablet |
| 04/13/2005 | CN1605346A Vacuum-electrolysis and flocculation reclaiming technology for preparing |
| 04/13/2005 | CN1196708C Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl)-1h-indol-5-ols |
| 04/13/2005 | CN1196707C General glycoside extracted from pomegranate leaf and astragalus root and its producing method |
| 04/13/2005 | CN1196681C (+)-Norcisapride useful for 5-HT3 and 5-HT4 mediated disorbers |
| 04/13/2005 | CN1196680C Modulators of dopamine neurotransmission |
| 04/13/2005 | CN1196496C Dry acid-chitosan complexes |
| 04/13/2005 | CN1196488C Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 04/13/2005 | CN1196482C Use of anticonvulsant derivatives for treating bulimia nervosa |
| 04/13/2005 | CN1196481C Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 04/12/2005 | US6878823 Substituted and unsubstitued 9-arylsulfone- 1,2,3,4,5,6-hexahydroazepino (4,5-b) indoles are useful in treatment of depression, obesity and other central nervous system disorders |
| 04/12/2005 | US6878732 5,7-diazaspiro(3.4)octane and -octene derivatives; treating diseases including emesis, depression, anxiety and cough |
| 04/12/2005 | US6878726 For therapy and prophylaxis inflammation, other inflammation associated disorders, such as arthritis, neurodegeneration and colon cancer, in mammals, dogs, cats or livestock animals |
| 04/12/2005 | US6878724 Polyarylcarboxamides useful as lipid lowering agents |
| 04/12/2005 | US6878718 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders |
| 04/12/2005 | US6878712 E.g., (R)-((2S,5R)-2-methyl-5-methyl-4-(4-carboxyphenyl-sulphonyl)-1-(3,3,3 -trifluoro-2-hydroxy-2-methylpropionyl)-piperazine); antidiabetic agents |
| 04/12/2005 | US6878707 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
| 04/12/2005 | US6878701 Potassium channel blocking agents |
| 04/12/2005 | US6878690 Compounds and methods |
| 04/12/2005 | US6878529 Compounds for the treatment of sexual dysfunction |
| 04/12/2005 | CA2293247C 4-phenylpiperidine compounds |
| 04/12/2005 | CA2252576C Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals |
| 04/12/2005 | CA2229316C Calcitriol derivatives and their uses |
| 04/12/2005 | CA2194471C Bis-piperidinyl non-peptidyl tachykinin receptor antagonist |
| 04/07/2005 | WO2005031347A1 Methods |
| 04/07/2005 | WO2005030975A1 METHOD OF PREPARING α-GLYCOSYLISOQUERCITRIN, INTERMEDIATE THEREFOR, AND BY-PRODUCT |
| 04/07/2005 | WO2005030758A1 Pyrimidine and pyridine derivatives useful as hmg-coa reductase inhibitors and method of preparation thereof |
| 04/07/2005 | WO2005030754A1 Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity |
| 04/07/2005 | WO2005030737A1 Phenylene derivative having tetrazole ring or thiazolidinedione ring |
| 04/07/2005 | WO2005030735A1 Triazines derivatives as cell adhesion inhibitors |
| 04/07/2005 | WO2005030734A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (ghs-r) antagonists |
| 04/07/2005 | WO2005030716A1 Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1 |
| 04/07/2005 | WO2005030715A1 Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors |
| 04/07/2005 | WO2005030698A1 Process for the preparation of voglibose |
| 04/07/2005 | WO2005030694A1 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 04/07/2005 | WO2005030333A2 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 04/07/2005 | WO2005030332A2 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 04/07/2005 | WO2005030255A1 METHOD OF TREATING DIABETES BY INHIBTING DEGRADATION OF AT LEAST ONE OF CREBL1, ATF6 and HNF-4α BY HtrA2 |
| 04/07/2005 | WO2005030236A1 Substance having intrahepatic glyconeogenesis inhibiting activity and food or food additive containing the substance |
| 04/07/2005 | WO2005030235A1 Method of processing ginseng for medicinal use and composition |
| 04/07/2005 | WO2005030234A1 Mulberry leaf extract/ocimum containing composition |
| 04/07/2005 | WO2005030233A1 Active oxygen scavenging agent and process for producing the same |
| 04/07/2005 | WO2005029980A1 Composition with relieved unpleasant odor or taste of cysteines |
| 04/07/2005 | WO2005021566A3 Glucopyranosyloxy- pirazoles, drugs containing said compounds the use and production method thereof |
| 04/07/2005 | WO2005016323A3 Use of c-kit inhibitors for treating type ii diabetes |
| 04/07/2005 | WO2005007647A9 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 04/07/2005 | WO2004113289A3 Glycosidase inhibitors and methods of synthesizing same |
| 04/07/2005 | WO2004108064A3 Diosgenin-based composition suitable for topical application |
| 04/07/2005 | WO2004083380A3 Methods and compositions for modulating glycogen synthesis and breakdown |
| 04/07/2005 | WO2004046732A8 Methods for screening compounds modulating cholesterol flux and uses thereof |
| 04/07/2005 | WO2004023100A3 Cd56 positive human adult pancreatic endocrine progenitor cells |
| 04/07/2005 | WO2004006847A3 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 04/07/2005 | WO2003030612A3 Methods for modulating activity of the fxr nuclear receptor |
| 04/07/2005 | US20050075489 DSP-5 dual-specificity phosphatase |
| 04/07/2005 | US20050075396 Modulation of type 2 diabetes and drug delivery |
| 04/07/2005 | US20050075391 Nitric oxide donor composition and method for treatment of anal disorders |
| 04/07/2005 | US20050075386 Drugs from indocasbazole derivatives |
| 04/07/2005 | US20050075378 Modulators of peroxisome proliferator activated receptors (ppar) |
| 04/07/2005 | US20050075377 Compounds for elevating plasma lipid levels with prodrugs for humans and other mammals |
| 04/07/2005 | US20050075367 Ester compound and medicinal use thereof |
| 04/07/2005 | US20050075349 Xanthine phosphodiesterase V inhibitors |
| 04/07/2005 | US20050075344 Melanocortin receptor agonists |
| 04/07/2005 | US20050075338 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 04/07/2005 | US20050075336 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |